


FALL 2023 VACCINES

	WHAT are the options?	WHO is eligible?	HOW well do they work?	WHEN should I get it?
 INFLUENZA	A shot that targets 4 strains of seasonal flu.	6 months and older	Typically reduces the risk of going to the doctor by 40-60%.	October is ideal, as vaccine protection wanes over a season.
 COVID-19	Updated vaccine formula targeting XBB—an Omicron subvariant. Options: Moderna and Pfizer (mRNA) and Novavax (protein)	TBD <i>CDC will decide in mid-to-late September.</i>	Last year, the fall COVID-19 vaccine provided 40-60% additional effectiveness against severe disease.	For protection against severe disease , get it anytime. For protection against infection , It's best to get it right before a wave, which can be challenging to time.
 RSV (OLDER ADULTS)	Options: GSK and Pfizer <i>They are slightly different in design, but only at a microscopic level.</i>	60 years and older	82-86% efficacy against severe disease.	Protection is durable. Get when it's available; no need to juggle timing.
 RSV (PREGNANCY)	Pfizer is actively seeking approval.	Pregnant people <i>(Protection will pass to baby for protection in first 6 months of life.)</i>	82% efficacy in preventing hospitalization in first 3 months of life. 69% efficacy after 6 months.	It's not available yet, but once approved, get at 24 to 36 weeks of pregnancy.
 RSV ANTIBODY	A new monoclonal antibody by AstraZeneca. <i>This is not a vaccine (doesn't teach the body to make antibodies) but rather a proactive medication (provides antibodies).</i>	All infants <8 months High-risk infants 8-19 months	Reduces risk of hospitalization and healthcare visits by ~80%.	Will be available soon. Protection lasts 4-6 months.

By: Katelyn Jetelina, MPH PHD and Caitlin Rivers, MPH PHD.

FALL 2023 VACCINES

	WHAT are the options?	WHO is eligible?	HOW well do they work?	WHEN should I get it?
 INFLUENZA	A shot that targets 4 strains of seasonal flu.	6 months and older	Typically reduces the risk of going to the doctor by 40-60%.	October is ideal, as vaccine protection wanes over a season.
 COVID-19	Updated vaccine formula targeting XBB—an Omicron subvariant. Options: Moderna, Pfizer (mRNA) and Novavax (protein)	TBD <i>CDC will decide in mid-to-late September.</i>	Last year, the fall COVID-19 vaccine provided 40-60% additional effectiveness against severe disease.	For protection against severe disease , get it anytime. For protection against infection , it's best to get it right before a wave, which can be challenging to time.
 RSV (OLDER ADULTS)	Options: GSK and Pfizer <i>They are slightly different in design, but only at a microscopic level.</i>	60 years and older	82-86% efficacy against severe disease.	Protection is durable. Get when it's available; no need to juggle timing.
 RSV (PREGNANCY)	Pfizer is actively seeking approval.	Pregnant people <i>(Protection will pass to baby for protection in first 6 months of life.)</i>	82% efficacy in preventing hospitalization in first 3 months of life. 69% efficacy after 6 months.	It's not available yet, but once approved, get at 24 to 36 weeks of pregnancy.
 RSV ANTIBODY	A new monoclonal antibody by AstraZeneca. <i>This is not a vaccine (doesn't teach the body to make antibodies) but rather a proactive medication (provides antibodies).</i>	All infants <8 months High-risk infants 8-19 months	Reduces risk of hospitalization and healthcare visits by ~80%.	Will be available soon. Protection lasts 4-6 months.

By: Katelyn Jetelina, MPH PHD and Caitlin Rivers, MPH PHD.